Cargando…

Impact of PD-L1 Scores and Changes on Clinical Outcome in Rectal Cancer Patients Undergoing Neoadjuvant Chemoradiotherapy

Reports on the prognostic role of programmed death-ligand 1 (PD-L1) expression in rectal cancer are controversial. We investigated expression patterns and changes of PD-L1 in rectal cancer patients undergoing neoadjuvant chemoradiotherapy (CRT). Seventy-two patients diagnosed with rectal cancer and/...

Descripción completa

Detalles Bibliográficos
Autores principales: Huemer, Florian, Klieser, Eckhard, Neureiter, Daniel, Schlintl, Verena, Rinnerthaler, Gabriel, Pagès, Franck, Kirilovsky, Amos, El Sissy, Carine, Iglseder, Wolfgang, Singhartinger, Franz, Jäger, Tarkan, Dinnewitzer, Adam, Zaborsky, Nadja, Steiner, Markus, Greil, Richard, Weiss, Lukas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7563312/
https://www.ncbi.nlm.nih.gov/pubmed/32867256
http://dx.doi.org/10.3390/jcm9092775
_version_ 1783595463004389376
author Huemer, Florian
Klieser, Eckhard
Neureiter, Daniel
Schlintl, Verena
Rinnerthaler, Gabriel
Pagès, Franck
Kirilovsky, Amos
El Sissy, Carine
Iglseder, Wolfgang
Singhartinger, Franz
Jäger, Tarkan
Dinnewitzer, Adam
Zaborsky, Nadja
Steiner, Markus
Greil, Richard
Weiss, Lukas
author_facet Huemer, Florian
Klieser, Eckhard
Neureiter, Daniel
Schlintl, Verena
Rinnerthaler, Gabriel
Pagès, Franck
Kirilovsky, Amos
El Sissy, Carine
Iglseder, Wolfgang
Singhartinger, Franz
Jäger, Tarkan
Dinnewitzer, Adam
Zaborsky, Nadja
Steiner, Markus
Greil, Richard
Weiss, Lukas
author_sort Huemer, Florian
collection PubMed
description Reports on the prognostic role of programmed death-ligand 1 (PD-L1) expression in rectal cancer are controversial. We investigated expression patterns and changes of PD-L1 in rectal cancer patients undergoing neoadjuvant chemoradiotherapy (CRT). Seventy-two patients diagnosed with rectal cancer and/or treated with fluorouracil-based neoadjuvant CRT at the Department of Internal Medicine III of the Paracelsus Medical University Salzburg (Austria) between January 2003 and October 2012 were included. PD-L1 scoring was performed according to the tumor proportion score (TPS), combined positive score (CPS), and immune cell score (IC). PD-L1 TPS prior to neoadjuvant CRT had a statistically significant impact on survival (median: ≤1%: 95.4 months (95% CI: 51.8—not reached) vs. >1%: not reached, p = 0.03, log-rank). Patients with a PD-L1 TPS ≤1% prior to and after CRT showed an inferior survival compared to all other patients (median: 56.7 months (95% CI: 51.4—not reached) vs. not reached, p = 0.005, log-rank). In multivariate analysis, PD-L1 TPS prior to neoadjuvant CRT (>1% vs. ≤1%, hazard ratio: 0.29 (95% CI: 0.11–0.76), p = 0.01) remained independently associated with survival. In conclusion, low PD-L1 TPS was associated with inferior survival in rectal cancer patients undergoing neoadjuvant CRT. A prospective validation of the prognostic value of PD-L1 expression in rectal cancer patients within a clinical trial is necessitated.
format Online
Article
Text
id pubmed-7563312
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-75633122020-10-27 Impact of PD-L1 Scores and Changes on Clinical Outcome in Rectal Cancer Patients Undergoing Neoadjuvant Chemoradiotherapy Huemer, Florian Klieser, Eckhard Neureiter, Daniel Schlintl, Verena Rinnerthaler, Gabriel Pagès, Franck Kirilovsky, Amos El Sissy, Carine Iglseder, Wolfgang Singhartinger, Franz Jäger, Tarkan Dinnewitzer, Adam Zaborsky, Nadja Steiner, Markus Greil, Richard Weiss, Lukas J Clin Med Article Reports on the prognostic role of programmed death-ligand 1 (PD-L1) expression in rectal cancer are controversial. We investigated expression patterns and changes of PD-L1 in rectal cancer patients undergoing neoadjuvant chemoradiotherapy (CRT). Seventy-two patients diagnosed with rectal cancer and/or treated with fluorouracil-based neoadjuvant CRT at the Department of Internal Medicine III of the Paracelsus Medical University Salzburg (Austria) between January 2003 and October 2012 were included. PD-L1 scoring was performed according to the tumor proportion score (TPS), combined positive score (CPS), and immune cell score (IC). PD-L1 TPS prior to neoadjuvant CRT had a statistically significant impact on survival (median: ≤1%: 95.4 months (95% CI: 51.8—not reached) vs. >1%: not reached, p = 0.03, log-rank). Patients with a PD-L1 TPS ≤1% prior to and after CRT showed an inferior survival compared to all other patients (median: 56.7 months (95% CI: 51.4—not reached) vs. not reached, p = 0.005, log-rank). In multivariate analysis, PD-L1 TPS prior to neoadjuvant CRT (>1% vs. ≤1%, hazard ratio: 0.29 (95% CI: 0.11–0.76), p = 0.01) remained independently associated with survival. In conclusion, low PD-L1 TPS was associated with inferior survival in rectal cancer patients undergoing neoadjuvant CRT. A prospective validation of the prognostic value of PD-L1 expression in rectal cancer patients within a clinical trial is necessitated. MDPI 2020-08-27 /pmc/articles/PMC7563312/ /pubmed/32867256 http://dx.doi.org/10.3390/jcm9092775 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Huemer, Florian
Klieser, Eckhard
Neureiter, Daniel
Schlintl, Verena
Rinnerthaler, Gabriel
Pagès, Franck
Kirilovsky, Amos
El Sissy, Carine
Iglseder, Wolfgang
Singhartinger, Franz
Jäger, Tarkan
Dinnewitzer, Adam
Zaborsky, Nadja
Steiner, Markus
Greil, Richard
Weiss, Lukas
Impact of PD-L1 Scores and Changes on Clinical Outcome in Rectal Cancer Patients Undergoing Neoadjuvant Chemoradiotherapy
title Impact of PD-L1 Scores and Changes on Clinical Outcome in Rectal Cancer Patients Undergoing Neoadjuvant Chemoradiotherapy
title_full Impact of PD-L1 Scores and Changes on Clinical Outcome in Rectal Cancer Patients Undergoing Neoadjuvant Chemoradiotherapy
title_fullStr Impact of PD-L1 Scores and Changes on Clinical Outcome in Rectal Cancer Patients Undergoing Neoadjuvant Chemoradiotherapy
title_full_unstemmed Impact of PD-L1 Scores and Changes on Clinical Outcome in Rectal Cancer Patients Undergoing Neoadjuvant Chemoradiotherapy
title_short Impact of PD-L1 Scores and Changes on Clinical Outcome in Rectal Cancer Patients Undergoing Neoadjuvant Chemoradiotherapy
title_sort impact of pd-l1 scores and changes on clinical outcome in rectal cancer patients undergoing neoadjuvant chemoradiotherapy
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7563312/
https://www.ncbi.nlm.nih.gov/pubmed/32867256
http://dx.doi.org/10.3390/jcm9092775
work_keys_str_mv AT huemerflorian impactofpdl1scoresandchangesonclinicaloutcomeinrectalcancerpatientsundergoingneoadjuvantchemoradiotherapy
AT kliesereckhard impactofpdl1scoresandchangesonclinicaloutcomeinrectalcancerpatientsundergoingneoadjuvantchemoradiotherapy
AT neureiterdaniel impactofpdl1scoresandchangesonclinicaloutcomeinrectalcancerpatientsundergoingneoadjuvantchemoradiotherapy
AT schlintlverena impactofpdl1scoresandchangesonclinicaloutcomeinrectalcancerpatientsundergoingneoadjuvantchemoradiotherapy
AT rinnerthalergabriel impactofpdl1scoresandchangesonclinicaloutcomeinrectalcancerpatientsundergoingneoadjuvantchemoradiotherapy
AT pagesfranck impactofpdl1scoresandchangesonclinicaloutcomeinrectalcancerpatientsundergoingneoadjuvantchemoradiotherapy
AT kirilovskyamos impactofpdl1scoresandchangesonclinicaloutcomeinrectalcancerpatientsundergoingneoadjuvantchemoradiotherapy
AT elsissycarine impactofpdl1scoresandchangesonclinicaloutcomeinrectalcancerpatientsundergoingneoadjuvantchemoradiotherapy
AT iglsederwolfgang impactofpdl1scoresandchangesonclinicaloutcomeinrectalcancerpatientsundergoingneoadjuvantchemoradiotherapy
AT singhartingerfranz impactofpdl1scoresandchangesonclinicaloutcomeinrectalcancerpatientsundergoingneoadjuvantchemoradiotherapy
AT jagertarkan impactofpdl1scoresandchangesonclinicaloutcomeinrectalcancerpatientsundergoingneoadjuvantchemoradiotherapy
AT dinnewitzeradam impactofpdl1scoresandchangesonclinicaloutcomeinrectalcancerpatientsundergoingneoadjuvantchemoradiotherapy
AT zaborskynadja impactofpdl1scoresandchangesonclinicaloutcomeinrectalcancerpatientsundergoingneoadjuvantchemoradiotherapy
AT steinermarkus impactofpdl1scoresandchangesonclinicaloutcomeinrectalcancerpatientsundergoingneoadjuvantchemoradiotherapy
AT greilrichard impactofpdl1scoresandchangesonclinicaloutcomeinrectalcancerpatientsundergoingneoadjuvantchemoradiotherapy
AT weisslukas impactofpdl1scoresandchangesonclinicaloutcomeinrectalcancerpatientsundergoingneoadjuvantchemoradiotherapy